{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:48:56Z","timestamp":1782391736112,"version":"3.54.5"},"reference-count":43,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Vulnerable Brain Project","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate cannabidiol (CBD) in pediatric patients with autism spectrum disorder (ASD), fluent verbal language and an estimated full-scale IQ of 80 or above.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Preliminary evidence suggests CBD may ameliorate challenges associated with ASD. Whether CBD benefits pediatric ASD without accompanying intellectual or language impairment remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We enrolled 23 participants, ages 7.8\u201317.8 (Mean [M] = 11.3\u2009\u00b1\u20092.8) with ASD and IQ \u2265 80 in a 6-week Phase-2 open-label trial of \u226598% CBD (Epidiolex\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , 100 mg\/mL) at 3, 6, or 9 mg\/kg\/day using a Bayesian optimal interval dosing design. The primary endpoint was the CBD dose associated with the highest response rate (i.e., Clinical Global Impression Scale-Improvement [CGI-I] score = 1 or 2) on a target symptom domain designated individually based on informant report, standardized scales, and clinical observation. Secondary endpoints were effect sizes of changes from baseline in measures assessing ASD core and associated symptoms, and global functioning. Adverse events (AEs) were assessed weekly. Plasma CBD levels and clinical labs were obtained at the final visit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All 23 enrolled participants completed the trial. The highest response (62%) was observed at 9 mg\/kg\/day (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 8). Overall, 10 of 23 patients (44%) were responders. Response varied across domains: Irritability\/Tantrums (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 5, 60%), Social (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 8, 50%), Anxiety (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 5, 40%), Restricted, Repetitive Behaviors (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 4, 25%), and Sleep Problems (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 1, 0%). Dose correlated with individualized CGI-I (r = \u22120.42,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 23,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.04).\n                    <\/jats:p>\n                    <jats:p>\n                      Individualized domain CGI\u2013Severity scores improved from pre-(M = 4.6\u2009\u00b1\u20090.5) to post-(M = 3.9\u2009\u00b1\u20090.8) treatment, t\n                      <jats:sub>(22)<\/jats:sub>\n                      = \u22124.36,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2264 0.001;\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      = 0.91; 95%CI [0.37,1.03]. Social Responsiveness Scale-2 Total-Score (SRS2-T) had the largest effect size (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2264 0.001;\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      = 1.36, 95% CI [0.78\u20131.93]).\n                    <\/jats:p>\n                    <jats:p>Of 222 reported AEs, 27 unique AEs were considered treatment-related. Most AEs (93%) were mild and expected (82%); none was severe. The most frequent related AEs were increased salivation (30%), increased sleep duration (39%), sleepiness\/sedation (26%), increased dream activity (35%), and polyuria (22%). Vital signs, physical exams, weight, liver function tests, and complete blood counts were unaffected. CBD plasma levels did not correlate with response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this preliminary study, CBD was well tolerated; AEs were mild\u2013moderate. Mean SRS2-T and subscores decreased significantly with large effect sizes, shifting from the severe to the moderate range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier NCT03900923.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10445463261452514","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:11:16Z","timestamp":1779952276000},"page":"350-358","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9785-7072","authenticated-orcid":false,"given":"Jacqueline","family":"Lawson","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta R.","family":"Conlon","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Shalev","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige E.","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Yoncheva","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Troxel","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin","family":"Devinsky","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9192-9437","authenticated-orcid":false,"given":"Francisco Xavier","family":"Castellanos","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"5","key":"e_1_3_3_2_1","first-page":"485","article-title":"The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects","volume":"89","author":"Aman MG","year":"1985","unstructured":"Aman MG, , Singh NN, , Stewart AW, et al. The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89(5):485\u2013491.","journal-title":"Am J Ment Defic"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Aman MG Singh NN. Aberrant behavior checklist. East Aurora NY: Slosson 1986.","DOI":"10.1037\/t10453-000"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. \u2018Neurodevelopmental Disorders\u2019, in Diagnostic and Statistical Manual of Mental Disorders. 5th edn. Washington, DC: American Psychiatric Publishing, 2013; pp. 31\u201386.","edition":"5"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-018-3808-2"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-021-00420-2"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/fbp.0000000000000565"},{"key":"e_1_3_3_8_1","first-page":"157","article-title":"Assessing situational variation in children\u2019s problem behaviors: The Home and School Situations Questionnaires","author":"Barkley RA","year":"1987","unstructured":"Barkley RA. Assessing situational variation in children\u2019s problem behaviors: The Home and School Situations Questionnaires. Advances in Behavioral Assessment of Children and Families 1987:157\u2013176.","journal-title":"Advances in Behavioral Assessment of Children and Families"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.6"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/aur.1645"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-006-0327-3"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2869.1996.00251.x"},{"issue":"7","key":"e_1_3_3_13_1","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, , Targum SD. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-026-03815-y"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-013-2029-y"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1362361315593941"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1025014929212"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/b:jadd.0000005999.27178.55"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0021-7"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-006-0280-1"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.21037\/tp.2019.09.09"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2020.08.012"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1711351114"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-017-3350-7"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/aur.2257"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/080394801317084428"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31129-2"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-010-1012-0"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2015.07.033"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111176"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0333-8"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2020.0110"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/aur.1603"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.01.018"},{"key":"e_1_3_3_36_1","volume-title":"CARS2): Manual. Western Psychological Services","author":"Schopler E","year":"2010","unstructured":"Schopler E, , Bourgondien MEV, , Wellman GJ, et al. The Childhood Autism Rating Scale, second edition (CARS2): Manual. Western Psychological Services: Los Angeles, CA; Western Psychological Services. 2010."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss7402a1"},{"key":"e_1_3_3_38_1","volume-title":"Vineland Adaptive Behavior Scales","author":"Sparrow SS","year":"2016","unstructured":"Sparrow SS, , Cicchetti DV, , Saulnier CA, et al. Vineland Adaptive Behavior Scales. 3rd edn. PsychCorp. 2016.","edition":"3"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rasd.2014.06.008"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-025-06884-y"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molpha.2025.100017"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-0592"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109715"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00259"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10445463261452514","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10445463261452514","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10445463261452514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:49:28Z","timestamp":1782388168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10445463261452514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.1177\/10445463261452514"],"URL":"https:\/\/doi.org\/10.1177\/10445463261452514","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}